Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
14
01
2020
accepted:
09
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Ovarian cancer remains a significant challenge in women worldwide. Tumors of the high-grade serous carcinoma (HGSC) type represent the most common form of the disease. Development of new therapies for HGSC has been hampered by a paucity of preclinical models in which new drugs could be tested for target engagement and anti-tumor efficacy. Here, we systematically assessed in vivo growth of ovarian cancer cells, including six validated HGSC cell lines, in highly immunocompromised NSG mice by varying the injection site. We found that, with the exception of OVCAR3, HGSC cell lines COV318, COV362, KURAMOCHI, OVCAR4, and OVSAHO, generally demonstrate poor growth as either subcutaneous or intraperitoneal xenografts. Intrabursal injections performed with KURAMOCHI and COV362 cells did not improve tumor growth in vivo. Additional analysis revealed that OVSAHO and COV362 express moderate levels of estrogen receptor (ERα), which translated into improved growth of xenografts in the presence of 17β-Estradiol. Surprisingly, we also found that the growth of the widely used non-HGSC ovarian cell line SKOV3 could be significantly improved by estrogen supplementation. By describing successful establishment of estrogen-sensitive HGSC xenograft models, OVSAHO and COV362, this work will enable testing of novel therapies for this aggressive form of ovarian cancer.
Identifiants
pubmed: 32612269
doi: 10.1038/s41598-020-67533-1
pii: 10.1038/s41598-020-67533-1
pmc: PMC7329846
doi:
Substances chimiques
Estradiol
4TI98Z838E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10799Subventions
Organisme : Cancer Research UK
ID : C2739/A22897
Pays : United Kingdom
Références
Reid, B. M., Permuth, J. B. & Sellers, T. A. Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 14, 9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 (2017).
doi: 10.20892/j.issn.2095-3941.2016.0084
pubmed: 28443200
pmcid: 5365187
McCluggage, W. G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43, 420–432. https://doi.org/10.1097/PAT.0b013e328348a6e7 (2011).
doi: 10.1097/PAT.0b013e328348a6e7
pubmed: 21716157
Prat, J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460, 237–249. https://doi.org/10.1007/s00428-012-1203-5 (2012).
doi: 10.1007/s00428-012-1203-5
pubmed: 22322322
Lisio, M. A., Fu, L., Goyeneche, A., Gao, Z. H. & Telleria, C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20040952 (2019).
doi: 10.3390/ijms20040952
pubmed: 30823606
pmcid: 6412681
Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262–1270. https://doi.org/10.1038/s41588-018-0179-8 (2018).
doi: 10.1038/s41588-018-0179-8
pubmed: 30104763
pmcid: 6130818
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615. https://doi.org/10.1038/nature10166 (2011).
doi: 10.1038/nature10166
Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56. https://doi.org/10.1002/path.2696 (2010).
doi: 10.1002/path.2696
pubmed: 20229506
pmcid: 3262968
Vang, R. et al. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study. Int. J. Gynecol. Pathol. 35, 48–55. https://doi.org/10.1097/PGP.0000000000000207 (2016).
doi: 10.1097/PGP.0000000000000207
pubmed: 26166714
pmcid: 4696053
Flesken-Nikitin, A., Choi, K. C., Eng, J. P., Shmidt, E. N. & Nikitin, A. Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63, 3459–3463 (2003).
pubmed: 12839925
Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376–1388. https://doi.org/10.1016/S0140-6736(13)62146-7 (2014).
doi: 10.1016/S0140-6736(13)62146-7
pubmed: 24767708
Cook, S. A. & Tinker, A. V. PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs 33, 255–273. https://doi.org/10.1007/s40259-019-00347-4 (2019).
doi: 10.1007/s40259-019-00347-4
pubmed: 30895466
Clark-Knowles, K. V., Garson, K., Jonkers, J. & Vanderhyden, B. C. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 313, 133–145. https://doi.org/10.1016/j.yexcr.2006.09.026 (2007).
doi: 10.1016/j.yexcr.2006.09.026
pubmed: 17070800
Clark-Knowles, K. V., Senterman, M. K., Collins, O. & Vanderhyden, B. C. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS ONE 4, e8534. https://doi.org/10.1371/journal.pone.0008534 (2009).
doi: 10.1371/journal.pone.0008534
pubmed: 20046869
pmcid: 2795167
Mullany, L. K. et al. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30, 3522–3536. https://doi.org/10.1038/onc.2011.70 (2011).
doi: 10.1038/onc.2011.70
pubmed: 21423204
pmcid: 3139785
Quinn, B. A. et al. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS ONE 4, e8404. https://doi.org/10.1371/journal.pone.0008404 (2009).
doi: 10.1371/journal.pone.0008404
pubmed: 20046879
pmcid: 2796165
Szabova, L. et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72, 4141–4153. https://doi.org/10.1158/0008-5472.CAN-11-3834 (2012).
doi: 10.1158/0008-5472.CAN-11-3834
pubmed: 22617326
pmcid: 3421072
Sherman-Baust, C. A. et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J. Pathol. 233, 228–237. https://doi.org/10.1002/path.4353 (2014).
doi: 10.1002/path.4353
pubmed: 24652535
pmcid: 4149901
Kim, J. et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. USA 109, 3921–3926. https://doi.org/10.1073/pnas.1117135109 (2012).
doi: 10.1073/pnas.1117135109
pubmed: 22331912
Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751–765. https://doi.org/10.1016/j.ccr.2013.10.013 (2013).
doi: 10.1016/j.ccr.2013.10.013
pubmed: 24332043
pmcid: 3917315
Zhang, S. et al. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat. Commun. 10, 5367. https://doi.org/10.1038/s41467-019-13116-2 (2019).
doi: 10.1038/s41467-019-13116-2
pubmed: 31772167
pmcid: 6879755
Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126. https://doi.org/10.1038/ncomms3126 (2013).
doi: 10.1038/ncomms3126
pubmed: 23839242
pmcid: 3715866
Mitra, A. K. et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol. Oncol. 138, 372–377. https://doi.org/10.1016/j.ygyno.2015.05.040 (2015).
doi: 10.1016/j.ygyno.2015.05.040
pubmed: 26050922
pmcid: 4528621
Elias, K. M. et al. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. Gynecol. Oncol. 139, 97–103. https://doi.org/10.1016/j.ygyno.2015.08.017 (2015).
doi: 10.1016/j.ygyno.2015.08.017
pubmed: 26321251
pmcid: 4587360
Sieh, W. et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 14, 853–862. https://doi.org/10.1016/S1470-2045(13)70253-5 (2013).
doi: 10.1016/S1470-2045(13)70253-5
pubmed: 23845225
pmcid: 4006367
Andersen, C. L. et al. Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin. Cancer Res. 23, 3802–3812. https://doi.org/10.1158/1078-0432.CCR-16-1501 (2017).
doi: 10.1158/1078-0432.CCR-16-1501
pubmed: 28073843
pmcid: 5503796
Liu, J. F., Hirsch, M. S., Lee, H. & Matulonis, U. A. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol. Oncol. 115, 401–406. https://doi.org/10.1016/j.ygyno.2009.08.023 (2009).
doi: 10.1016/j.ygyno.2009.08.023
pubmed: 19796795
Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer. 102, 1555–1577. https://doi.org/10.1038/sj.bjc.6605642 (2010).
doi: 10.1038/sj.bjc.6605642
pubmed: 20502460
pmcid: 2883160
Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477–6489. https://doi.org/10.4049/jimmunol.174.10.6477 (2005).
doi: 10.4049/jimmunol.174.10.6477
pubmed: 15879151
pmcid: 15879151
Shultz, L. D. et al. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb. Protoc.. 694–708, 2014. https://doi.org/10.1101/pdb.top073585 (2014).
doi: 10.1101/pdb.top073585
Dall, G., Vieusseux, J., Unsworth, A., Anderson, R. & Britt, K. low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J. Cancer 6, 1331–1336. https://doi.org/10.7150/jca.10890 (2015).
doi: 10.7150/jca.10890
pubmed: 26640593
pmcid: 4643089
Lee, J. M. et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Investig. 93, 528–542. https://doi.org/10.1038/labinvest.2013.41 (2013).
doi: 10.1038/labinvest.2013.41
pubmed: 23459371
Shaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A. & Vanderhyden, B. C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 10, 1032–1042. https://doi.org/10.1016/j.ymthe.2004.08.013 (2004).
doi: 10.1016/j.ymthe.2004.08.013
pubmed: 15564135
Hernandez, L. et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol. Oncol. 142, 332–340. https://doi.org/10.1016/j.ygyno.2016.05.028 (2016).
doi: 10.1016/j.ygyno.2016.05.028
pubmed: 27235858
pmcid: 4961516
Lau, K. M., Mok, S. C. & Ho, S. M. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. USA 96, 5722–5727. https://doi.org/10.1073/pnas.96.10.5722 (1999).
doi: 10.1073/pnas.96.10.5722
pubmed: 10318951
Hua, W., Christianson, T., Rougeot, C., Rochefort, H. & Clinton, G. M. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J. Steroid Biochem. Mol. Biol. 55, 279–289. https://doi.org/10.1016/0960-0760(95)00187-5 (1995).
doi: 10.1016/0960-0760(95)00187-5
pubmed: 8541224
Ciucci, A. et al. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers. Oncotarget 7, 8155–8171. https://doi.org/10.18632/oncotarget.6943 (2016).
doi: 10.18632/oncotarget.6943
pubmed: 26797759
pmcid: 4884983
Spillman, M. A. et al. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 70, 8927–8936. https://doi.org/10.1158/0008-5472.CAN-10-1238 (2010).
doi: 10.1158/0008-5472.CAN-10-1238
pubmed: 20959477
pmcid: 3804411
Kang, J. S. et al. Low dose estrogen supplementation reduces mortality of mice in estrogen-dependent human tumor xenograft model. Biol. Pharm. Bull. 32, 150–152. https://doi.org/10.1248/bpb.32.150 (2009).
doi: 10.1248/bpb.32.150
pubmed: 19122299
Bourdeau, V. et al. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol. Endocrinol. 18, 1411–1427. https://doi.org/10.1210/me.2003-0441 (2004).
doi: 10.1210/me.2003-0441
pubmed: 15001666
Marino, M., Galluzzo, P. & Ascenzi, P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics 7, 497–508. https://doi.org/10.2174/138920206779315737 (2006).
doi: 10.2174/138920206779315737
pubmed: 18369406
pmcid: 2269003
Sweeney, E. E., McDaniel, R. E., Maximov, P. Y., Fan, P. & Jordan, V. C. Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Horm. Mol. Biol. Clin. Investig. 9, 143–163. https://doi.org/10.1515/hmbci-2011-0004 (2012).
doi: 10.1515/hmbci-2011-0004
pubmed: 23308083
pmcid: 3539798